FIELD: medicine; pharmacology.
SUBSTANCE: pharmaceutical composition for treatment of immunologic diseases arising owing to undesirable activation of T lymphocytes is revealed. The composition contains in quality of active components two or more substances chosen from group, consisting of: the merged protein, capable to block linkage of a MHC molecule (the main complex of histocompatibility) a class II and its receptor, the merged protein, capable to block linkage of a co-stimulatory molecule and its receptor, the merged protein, capable to block linkage of a molecule of adhesion both its receptor, and the merged protein, capable to block linkage of cytokine and its receptor.
EFFECT: effective suppression of activity T lymphocytes.
10 cl, 20 dwg, 6 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETERODIMERIC IL-15 PROTEIN AND USE THEREOF | 2014 |
|
RU2689717C2 |
| SINGLE-STRANDED CD40 RECEPTOR AGONIST PROTEINS | 2016 |
|
RU2745801C2 |
| IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS | 2008 |
|
RU2506275C2 |
| METHODS FOR TREATMENT OF RHEUMATIC DISEASES BY USING SOLUBLE CTLA4 | 2001 |
|
RU2287340C2 |
| INTERLEUKIN 15 PROTEIN COMPLEX AND USE THEREOF | 2015 |
|
RU2711979C2 |
| COMPOSITIONS AND METHODS FOR TREATING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) | 2004 |
|
RU2411042C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| HOMODIMER PROTEIN CONSTRUCTION | 2011 |
|
RU2624041C2 |
| Fc RECEPTOR BINDING AGENTS BASED ON INVARIABLE REGION OF IMMUNOGLOBULIN | 2008 |
|
RU2549676C2 |
| SOLUBLE MUTANT CTLA4 AND USES THEREOF | 2001 |
|
RU2283847C2 |
